Acute PDE4 Inhibition Induces a Transient Increase in Blood Glucose in Mice

cAMP-phosphodiesterase 4 (PDE4) inhibitors are currently approved for the treatment of inflammatory diseases. There is interest in expanding the therapeutic application of PDE4 inhibitors to metabolic disorders, as their chronic application induces weight loss in patients and animals and improves gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Irelan, Daniel, Boyd, Abigail, Fiedler, Edward, Lochmaier, Peter, McDonough, Will, Aragon, Ileana V., Rachek, Lyudmila, Abou Saleh, Lina, Richter, Wito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963939/
https://www.ncbi.nlm.nih.gov/pubmed/36834669
http://dx.doi.org/10.3390/ijms24043260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963939/
https://www.ncbi.nlm.nih.gov/pubmed/36834669
http://dx.doi.org/10.3390/ijms24043260

Ejemplares similares